Background: To assess antitumor activity and toxicity of pemetrexed in metastatic breast cancer (MBC) patients previously treated with anthracyclines.
Introduction
Metastatic breast cancer (MBC) is moderately sensitive to chemotherapy. Classical anthracycline combinations such as 5-fluorouracil (5-FU)-adriamycin-cyclophosphamide (FAC), 5-fluorouracil-epirubicin-cyclophosphamide (FEC) and adriamycin-cyclophosphamide (AC) are the most frequently used first-line regimens for MBC, and result in objective responses in 50-80% of patients, with complete responses in 10-20% of patients [1] . Most MBC patients who respond to first-line anthracyclinecontaining chemotherapy obtain partial or complete relief of symptoms and, perhaps, a moderate increase in survival time [2] . The increasing use of anthracyclines in the adjuvant setting limits their use in relapsing patients. Fortunately, new pharmacological agents, such as taxanes, vinorelbine and capecitabine, have shown partial non-cross resistance with anthracyclines in MBC [3] [4] [5] . It is expected that these newer agents will soon be incorporated into adjuvant regimens and new cytotoxic agents will be needed for the treatment of disseminated disease.
Pemetrexed (ALIMTA ® ) is a novel, multi-targeted antifolate that has demonstrated antitumor activity in several preclinical models [6] . Inhibition of thymidylate synthase is the primary mechanism of action, which causes a decrease in thymidine necessary for DNA synthesis. Pemetrexed also inhibits dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyltransferase (GARFT), and to a lesser extent, aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT). DHFR inhibition depletes reduced folate pools; GARFT and AICARFT inhibition stop de novo purine biosynthesis. Evidence of pemetrexed's multitargeted mechanism of action is the ability of leucovorin and thymidine to circumvent the cytotoxic action in the human CCRF-CEM leukemia cell line [7] .
Through its multiple enzyme-inhibitory properties, pemetrexed is a broad-acting agent that demonstrates antitumor activity in non-small-cell lung [8] , colorectal [9] , pancreatic [10] , head and neck [11] , bladder [12] and gastric cancers [13] . Pemetrexed is currently in phase III studies for mesothelioma, non-small-cell lung and pancreatic cancers.
The antitumor activity of pemetrexed has been explored in a phase II study in a heterogeneous population of breast cancer patients [14] . Pemetrexed 600 mg/m 2 without vitamin supplementation induced responses in 28% of patients (10/36), many of which had received prior treatment with anthracyclines and/or taxanes. Grade 3-4 neutropenia was reported in 53% of patients, and neutropenic fever was reported in 13% of patients. In another phase II study, pemetrexed 500 mg/m 2 without vitamin supplementation was administered to MBC patients previously treated with both anthracyclines and taxanes [15] . The preliminary response rate was 19%, with 49% of patients experiencing grade 3-4 neutropenia. There were no reports of neutropenic fever. To further assess the antitumor activity of pemetrexed in breast cancer, we have conducted a large multicenter phase II study of pemetrexed in MBC patients previously treated with anthracyclines. We report here the final results of this study.
Patients and methods
This study was performed in 12 European centers located in France (three), Germany (three), Spain (two), UK (two), Austria (one) and the Czech Republic (one). Prior to study initiation, each site's ethical review board approved the protocol and informed consent documents in the local language.
Study objectives
The primary objective of this study was to determine the response rate of pemetrexed in MBC patients who had progressed during or following prior anthracycline/anthracenedione chemotherapy. Secondary objectives were to characterize the nature of the toxicity of pemetrexed and to measure time-toevent efficacy variables.
Patient selection criteria
Patients had to meet the following criteria: female; ≥18 years of age; a histological or cytological diagnosis of breast cancer; no more than one previous cytotoxic chemotherapy for locally advanced or metastatic breast cancer; progression since last dose of chemotherapy; an unlimited number of antitumor endocrine treatment was permitted if terminated at least 1 day prior to study entry; performance status 0-2 on the World Health Organization (WHO) scale; bidimensionally measurable disease; life expectancy of ≥12 weeks; patient compliance and geographic proximity that allowed adequate follow-up; adequate bone marrow reserves (absolute granulocyte counts >1.5 × 10 9 /l; hemoglobin ≥9 g/dl; platelets ≥100 × 10 9 /l); adequate hepatic function [bilirubin <1.5× upper limit of normal (ULN); aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <3× ULN (AST or ALT <5× ULN was acceptable if due to liver metastasis)]; adequate renal function (modified Cockcroft and Gault calculated creatinine clearance of ≥45 ml/min); written informed consent from patient; childbearing potential attenuated by use of an approved contraceptive method during and for 3 months after trial. Eligible patients had to have a prior chemotherapy regimen containing an anthracycline or anthracenedione agent.
Exclusion criteria included active infection, symptomatic brain metastases, clinically significant effusions (pleural or peritoneal), serum albumin ≤2.5 g/dl, hypercalcemia, second primary malignancies, need for concurrent administration of NSAIDS (e.g. aspirin, piroxicam, naproxen), prior high-dose chemotherapy requiring stem cell or bone marrow support and significant cardiac disease.
Treatment
Pemetrexed 600 mg/m 2 was administered as a 10 min i.v. infusion day 1, every 21 days. Dose adjustments at the start of a subsequent course of therapy were based on nadir absolute granulocyte counts (AGCs) and platelet counts or maximum non-hematological toxicity from the preceding course of therapy. Patients with grade 4 neutropenia for >5 days received 500 mg/m 2 in subsequent courses. Patients with grade 3 or 4 mucositis subsequently received 75% and 50% of the previous dose, respectively. For grade ≥3 non-hematological toxicity, the drug was withheld until resolution to grade ≤1 before proceeding.
Treatment was restarted at a 25% dose reduction if deemed appropriate by the treating physician. Dose escalations were not permitted. Absolute granulocyte counts had to be >1.5 × 10 9 /l and platelets >100 × 10 9 /l prior to the start of any cycle. A patient was discontinued from study if calculated or measured creatinine did not return to ≥45 ml/min within 42 days. No other chemotherapy, immunotherapy, hormonal therapy, radiation therapy (except for pain control) or experimental medications were permitted while the patients were on study. Dexamethasone 4 mg (or equivalent) was taken orally twice a day on the day before, the day of, and the day after receiving each dose of pemetrexed. Granulocyte colony stimulating factors (G-CSFs) were used only for patients who had grade 4 neutropenia for at least 5 days, neutropenic fever or documented infection while neutropenic at the investigator's discretion. G-CSFs were discontinued at least 24 h prior to initiation of the next cycle. Leucovorin was allowed for any patient who developed grade 3 or 4 mucositis or grade 4 myelosuppression lasting ≥5 days.
Response evaluation
No more than 4 weeks before enrolling, each patient was assessed by radiological imaging (excluding ultrasound) for tumor measurement. The same method used at baseline was utilized consistently for tumor assessment and was to be repeated every alternate cycle, 3-4 weeks after receiving the last dose and every 3 months until death. Tumor responses evaluated by physical examination were recorded every 3 weeks. Response was categorized according to South West Oncology Group (SWOG) criteria. The duration of response was defined as the time from first objective status assessment of a response to the first time of progression or death due to any cause. The time to progressive disease was defined as the time from the date of study enrollment until the date of progressive disease or death due to any cause. Patients who were alive without progression or were lost to follow-up were censored for time to progressive disease at the time they were last known to be alive and progression-free. Survival was defined as the time from study entry to time of death due to any cause.
Toxicity
Hematology was performed up to 3 days prior to the start of each cycle and weekly thereafter. If the AGC was <0.75 × 10 9 /l or the platelet count was <50 × 10 9 /l, the patient was re-tested every other day to document the duration of neutropenia and/or thrombocytopenia. Blood chemistry, urinalysis and calculated or measured creatinine clearance were performed up to 3 days prior to the start of each new cycle. A central laboratory performed the blood chemistries, calculated creatinine clearance and urinalysis. All toxicity was graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC, 1993).
Data management and statistical methods
All relevant data in the trial were submitted to in situ monitoring at the participating institutions, according to Good Clinical Practice guidelines. The study was a single-arm, open-label, non-randomized trial to observe two groups of patients:
• Group A. Anthracycline/anthracenedione-refractory patients (disease progression within 30 days of anthracycline/anthracenedione therapy).
• Group B. Anthracycline/anthracenedione-failure patients (disease progression ≥30 days after completion of anthracycline/anthracenedione therapy).
A two-stage Fleming [16] design was implemented. For group A, 20 patients were in the first stage of the study and 15 patients in the second stage. For group B, 15 patients were in the first stage of the study and 20 patients in the second stage. For group A, the study had an 86% power to test the hypothesis of ≤5% versus ≥20% tumor response rate at a 0.06 one-sided α level. For group B, the study had an 81% power to test the hypothesis of ≤10% versus ≥25% tumor response rate at a 0.06 one-sided α level. Outcomes [including a 95% confidence interval (CI)] comprised the following: tumor response rate, Kaplan-Meier curves for survival, time to treatment failure, time to progressive disease and duration of response.
Results
Between July 1997 and April 1999, a total of 77 patients were entered into the study (32 in the anthracycline-refractory and 45 in the anthracycline-failure subgroups). Two patients did not meet study entry criteria and were discontinued prior to treatment. Seventy-five patients were considered eligible and received pemetrexed. In the anthracycline-failure arm, 45 patients were enrolled and treated, 42 of whom were qualified for the efficacy analysis. In the anthracycline-refractory subgroup, 30 patients were enrolled and treated and all were considered for the efficacy analysis. Forty-seven patients received previous adjuvant chemotherapy, 69 patients chemotherapy for metastatic disease and 41 patients received both adjuvant and palliative therapies. One line of metastatic endocrine treatment was administered to 14 patients and 18 received two or more lines. Table 1 contains the characteristics of 75 enrolled patients.
Antitumor activity
Of the 72 evaluable patients, there were three complete responders (CRs) and 12 partial responders (PRs), yielding a response rate (RR) of 21% (95% CI 12% to 32%); 31 patients (43%) achieved stable disease. Among the patients who qualified, the median duration of response was 5.5 months (95% CI 3.2-8.1 months). Response rates in the anthracycline-refractory and anthracyclinefailure groups were 17% (one CR and four PR) and 24% (two CR and eight PR), respectively. Responses were observed at all disease sites ( Table 2 ). As previously reported in an interim analysis [17] , the response rate in a subset of 31 patients previously treated with anthracyclines and taxanes was 26% (one CR and seven PRs).
Median time to progression (TTP) was 3.4 months. The estimated median TTP for the failure group was 4.6 months (95% CI 3.3-6.2 months) and the median TTP for the refractory group was 2.5 months (95% CI 1.4-3.2 months).
Overall survival of 72 patients evaluable for response is shown in Figure 1 . The median overall survival for the entire population was 10.7 months. The estimated median survival time for the failure group was 13 months (95% CI 8.7-n/a months) and the median survival time for the refractory group was 5.7 months (95% CI 3.2-12 months). The median survival time of the subset of 31 patients pretreated with anthracyclines and taxanes was 9.2 months.
Toxicity
A total of 301 cycles of study drug were administered to the 75 enrolled patients. Patients received a median of three cycles of pemetrexed (range 1-14 cycles). There were no dose omissions; however, 15/75 patients (20%) were administered reduced doses per protocol, primarily due to myelosuppression. Out of 301 doses, 42 (14%) were delayed, again, primarily due to myelosuppression and rash.
Toxicity is listed in Table 3 . Grade 3-4 neutropenia was experienced by 56% of patients, with 12% having neutropenic fever. Grade 3-4 thrombocytopenia was seen in 19% of patients. Fourteen per cent and 10% of patients required red blood cell and platelets transfusions, respectively.
The most common non-hematological laboratory abnormalities were elevated levels of serum alkaline phosphatase and transaminases, which were mild and reversible in most patients. The most frequent non-laboratory grade 3-4 toxicities were reported for skin rash (10%), nausea (12%), vomiting (9%), fatigue (10%) and stomatitis (5%). Hair loss was infrequent and mild.
Eleven of 75 enrolled patients (15%) discontinued the study due to adverse events; for six of 11 patients, the adverse event was considered serious requiring hospitalization. The events were as follows: skin rash (four patients), anemia (two), abnormal liver function tests (two), leukopenia (one), vomiting (one) and abdominal pain (one). Nine patients (12%) experienced neutropenic fever. Four patients (5%) had episodes of various infections characterized as related to study drug.
Four patients died while on study but only one death (1.3%) was attributed to the study drug (neutropenic sepsis).
Discussion
In spite of the positive impact of anthracycline-based adjuvant therapy upon the natural history of early-stage breast cancer, a significant proportion of these women experience relapsed breast cancer. This observation fuels the search for new, non-crossresistant treatment options for breast cancer patients previously exposed to anthracyclines.
Vinorelbine yielded a RR of 34%, median TTP of 4.5 months, and median overall survival of 16.8 months in 107 women receiving first-or second-line treatment for advanced breast cancer. Among patients receiving first-line treatment, grade 3-4 toxicity consisted of neutropenia (82%) and asthenia (10%); among the second-line treatment patients, grade 3-4 toxicity consisted of neutropenia (78%) and asthenia (13%) [18] . Paclitaxel has been extensively studied in advanced breast cancer. In a study of 267 patients previously exposed to two chemotherapy regimens (including anthracyclines), the RR was 23%, median TTP was 4.0 months and median overall survival was 12.0 months. Reported grade 3-4 toxicity included neutropenia (80%), thrombocytopenia (15%) and infection (14%) [19] . Docetaxel resulted in a RR of 53%, TTP of 4.0 months and median overall survival of 9.0 months in 35 patients with anthracycline-resistant breast cancer [20] . In this study, grade 3-4 toxicity included neutropenia (88%), stomatitis (25%) and rash (14%). Lastly, capecitabine resulted in a RR of 20%, median TTP of 3.1 months and median overall survival of 12.8 months in 163 patients with paclitaxel-resistant and anthracycline-exposed breast cancer; in a retrospectively defined group of patients demonstrating disease progression following anthracycline and paclitaxel exposure, the RR was 29% [5] . Reported grade 3-4 laboratory toxicities included neutropenia (5%) and total bilirubin elevation (12%). Moderate to severe nonlaboratory toxicities included hand-foot syndrome (42%), diarrhea (30%), nausea (27%), vomiting (20%) and fatigue (25%).
The current trial demonstrates promising single-agent activity for pemetrexed in MBC patients pretreated with anthracyclines with a RR of 21%, comparable with the response rates in the aforementioned studies of pemetrexed. Responses were seen in both anthracycline-refractory (17%) and anthracycline-failure patients (24%), as well as in all sites of disease. Prior palliative endocrine treatment did not appear to influence response to pemetrexed. Although 71% of patients received previous 5-FU treatment (another thymidylate synthase inhibitor), prior 5-FU therapy did not appear to have an adverse effect upon response to pemetrexed. The median duration of response was 5.5 months and the median survival of the entire population was 10.7 months. The activity of pemetrexed does not appear to be affected by prior exposure to taxanes, as a 26% RR was observed in a subset of 31 patients pretreated with both anthracyclines and taxanes.
The main toxicities of pemetrexed were myelosuppression, skin rash and mucositis. Myelosuppression, particularly grade 3-4 neutropenia, was the most common toxicity and occurred in 56% of patients. Neutropenic fever was found in 12% of patients. One patient (1.3%) died from neutropenic sepsis, and this was the only drug-related death in the trial. Grade 3-4 thrombocytopenia was present in nearly 20% of patients, although only 10% necessitated platelet transfusions. Skin rash was present in 60% of patients, but in most cases was mild and easily prevented in subsequent courses with premedication with antihistaminics and corticosteroids. Thirtyseven per cent of patients presented some degree of stomatitis, but was severe in only 5%. Liver enzyme elevations were seen in many patients, but they were mild and reversible in most cases. Niyikiza et al. [21] studied toxicity in pemetrexed-treated patients and observed that baseline homocysteine levels correlated with severe treatment-induced toxicities, especially myelosuppression and mucositis. Plasma homocysteine concentration is a sensitive marker of vitamin B 12 and folate pools, and was found to be elevated in those patients who developed severe toxicity with pemetrexed. These observations prompted folic acid and vitamin B 12 supplementation for all patients treated in pemetrexed studies since December 1999. In the current study, toxicity was manageable even without vitamin supplementation. Of the 11 patients discontinued from the study due to adverse events, only six experienced events serious enough to require hospitalization. Fifteen patients (20%) had dose reductions and 22 patients (29%) had treatment delays due to toxicity. This toxicity profile does not differ greatly from those reported for other cytotoxic agents presently used in the treatment of refractory breast cancer.
With the increasing evidence of survival benefits with the adjuvant use of anthracyclines and taxanes, patients are now receiving these drugs earlier in their course of treatment. Because of this trend, the need for cytotoxic drugs with antitumor activity in MBC patients with prior anthracyclines and taxanes is evident. Thus far, only vinorelbine and capecitabine have shown activity in this patient population [5, [22] [23] [24] .
Our study demonstrates that pemetrexed possesses significant antitumor activity in MBC patients pretreated with anthracyclines, including those patients pretreated with anthracyclines and taxanes. Results from this study compare well with those reported for vinorelbine, paclitaxel, docetaxel and capecitabine in terms of overall RR (20-53%) and overall survival (9.0-16.8 months). In our study, neutropenia was the primary toxicity associated with pemetrexed therapy. Grade 3/4 neutropenia occurred in 56% of patients, which compares favorably with rates reported for docetaxel (88%), and did not require G-CSF support as with high-dose vinorelbine. Importantly, pemetrexed is easy to administer as a 10 min i.v. infusion once every 21 days. Considering the encouraging efficacy, manageable toxicity and convenience to the patient and clinic, pemetrexed deserves further study in the treatment of advanced breast cancer.
